Natural T, γδ, and NK cells in mycobacterial, Salmonella, and human immunodeficiency virus infections

被引:35
作者
Jason, J
Buchanan, I
Archibald, LK
Nwanyanwu, OC
Bell, M
Green, TA
Eick, A
Han, A
Razsi, D
Kazembe, PN
Dobbie, H
Midathada, M
Jarvis, WR
机构
[1] Ctr Dis Control, Natl Ctr Infect Dis, Immunol Branch, Div AIDS STD & TB Lab Res, Atlanta, GA 30333 USA
[2] Ctr Dis Control, Natl Ctr Infect Dis, HIV Immunol & Diagnost Branch, Atlanta, GA 30333 USA
[3] Ctr Dis Control, Natl Ctr Infect Dis, Invest & Prevent Branch, Hosp Infect Program, Atlanta, GA 30333 USA
[4] Ctr Dis Control & Prevent, Off Global Hlth, Atlanta, GA USA
[5] Minist Hlth & Populat, Lilongwe Cent Hosp, Lilongwe, Malawi
[6] Minist Hlth & Populat, Community Hlth Sci Unit, Lilongwe, Malawi
关键词
D O I
10.1086/315740
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
NK cells, gamma delta T cell antigen receptor chain-positive cells, and CD3(+)CD16/56(+) (natural T [NT]) cells are involved in innate immunity and immunoregulation; however, their role in clinical infection is not well defined. Cytofluorometric analysis was used to examine peripheral blood from bacteremic, nonbacteremic, and healthy human immunodeficiency virus (HIV)-positive and -negative persons in Malawi, Africa. Mycobacteremia was associated with a higher proportion of CD3(+)CD8(-) gamma delta cells (median, 16.6% a vs. 0.7% for all other cells; P < .001), and Salmonella bacteremia was associated with a higher proportion of NT cells (4.3% vs. 2.2%; P = .002). HIV plasma RNA levels were weakly positively correlated with NT cells (r(s) = .39; P = .002), NK cells (r(s) = .38; P = .003), and gamma delta cells (r(s) = .43; P < .001). Compared with patients who survived, patients who died had a higher percentage of NT cells (3.7% vs. 1.9%; P = .017) and a higher percentage of NT cells that spontaneously produced interferon-gamma (2.4% vs. 1.2%; P = .035). The data support the clinical relevance of gamma delta and NT cells in mycobacterial, Salmonella, and HIV infections and of NT cells in mortality.
引用
收藏
页码:474 / 481
页数:8
相关论文
共 30 条
[1]   GAMMA-DELTA-LYMPHOCYTES-T IN HUMAN TUBERCULOSIS [J].
BARNES, PF ;
GRISSO, CL ;
ABRAMS, JS ;
BAND, H ;
REA, TH ;
MODLIN, RL .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (03) :506-512
[2]  
Battistini L, 1997, J IMMUNOL, V159, P3723
[3]   Phenotypically activated γδ T lymphocytes in the peripheral blood of patients with tuberculosis [J].
Behr-Perst, SI ;
Munk, ME ;
Schaberg, T ;
Ulrichs, T ;
Schulz, RJ ;
Kaufmann, SHE .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (01) :141-149
[4]   Mouse CD1-specific NK1 T cells: Development, specificity, and function [J].
Bendelac, A ;
Rivera, MN ;
Park, SH ;
Roark, JH .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :535-562
[5]   CRYSTALLIZATION AND PRELIMINARY-X-RAY DIFFRACTION ANALYSIS OF THE BETA-CHAIN OF A T-CELL ANTIGEN RECEPTOR [J].
BOULOT, G ;
BENTLEY, GA ;
KARJALAINEN, K ;
MARIUZZA, RA .
JOURNAL OF MOLECULAR BIOLOGY, 1994, 235 (02) :795-797
[6]   The murine nonclassical class I major histocompatibility complex-like CD1.1 molecule protects target cells from lymphokine-activated killer cell cytolysis [J].
Chang, CS ;
Brossay, L ;
Kronenberg, M ;
Kane, KP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (03) :483-491
[7]   Bacterial antigen activation of V delta 1 and V delta 2 gamma delta T cells of persons infected with human immunodeficiency virus type 1 [J].
Chervenak, KA ;
Lederman, MM ;
Boom, WH .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (02) :429-433
[8]   Disseminated infection due to rapidly growing mycobacteria in immunocompetent hosts presenting with chronic lymphadenopathy: A previously unrecognized clinical entity [J].
Chetchotisakd, P ;
Mootsikapun, P ;
Anunnatsiri, S ;
Jirarattanapochai, K ;
Choonhakarn, C ;
Chaiprasert, A ;
Ubol, PN ;
Wheat, LJ ;
Davis, TE .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (01) :29-34
[9]   STIMULATION OF HUMAN GAMMA-DELTA T-CELLS BY NONPEPTIDIC MYCOBACTERIAL LIGANDS [J].
CONSTANT, P ;
DAVODEAU, F ;
PEYRAT, MA ;
POQUET, Y ;
PUZO, G ;
BONNEVILLE, M ;
FOURNIE, JJ .
SCIENCE, 1994, 264 (5156) :267-270
[10]  
Fehniger TA, 1998, J IMMUNOL, V161, P6433